Stockscreener 앱 받기
25.18
5.93%
1.41
Pacira Biosciences Inc 주식(PCRX)의 최신 뉴스
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Pacira announces layoffs due to efficiencies in Exparel production - MSN
Doma Perpetual's 5.7% Stake in Pacira Biosciences: A Catalyst for Governance Change or Strategic Alignment? - AInvest
Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $25.75 - Defense World
Will Pacira BioSciences Inc. stock recover after recent dropSwing Trade Entry and Exit Point Analysis - Newser
Is Pacira BioSciences Inc. building a consolidation baseAI Trading Forecast Based on Big Data - Newser
How Pacira BioSciences Inc. stock performs during market volatilityGrowth Watchlist for Long Term Positioning - Newser
Signal strength of Pacira BioSciences Inc. stock in tech scannersSecure Buy Strategy Based on Risk Parameters - Newser
Order flow analysis tools used on Pacira BioSciences Inc.Free Trade Insight With Community Collaboration - Newser
Real time alert setup for Pacira BioSciences Inc. performanceReal-Time Investment Picks with Accuracy - Newser
Doma Perpetual Discloses 5.7% Stake in Pacira Biosciences - MarketScreener
Can machine learning forecast Pacira BioSciences Inc. recoveryRisk Balanced Picks for Safer Trading - Newser
Trend analysis for Pacira BioSciences Inc. this weekLow Volatility Stock Analysis With Confidence - Newser
Detecting price anomalies in Pacira BioSciences Inc. with AIFree Chart Breakout Buy Signal Detection - Newser
Pacira BioSciences, Inc. (NASDAQ:PCRX) Position Lifted by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
Earnings visualization tools for Pacira BioSciences Inc.Free Daily Growth Stock Pick Reports - Newser
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Can Pacira BioSciences Inc. rally from current levelsStrong Buy Opportunity with Volume Support - Newser
Pacira Biosciences Q2 Earnings Call Highlights Growth and Strategy Amid Challenges - AInvest
Pacira BioSciences Reports Q2 2025 Results: EPS of -$0.11 Misses Estimates, Revenue at $181.1 Million Below Expectations - AInvest
Pacira BioSciences Reports Q2 2025 Financial Results: $181.1M Revenue, Net Loss of $4.8M - AInvest
New Product Launches: Will They Boost Pacira BioSciences Inc. Stock in 2025Momentum Entry Alerts with Risk Control - Newser
Pacira Biosciences shares rise 2.09% intraday after Q2 revenue beat expectations. - AInvest
Pacira Biosciences Q2 Non-GAAP Earnings Fall, Revenue Rises; Updates 2025 Sales Forecast - MarketScreener
Pacira BioSciences Posts Strong Q2 Growth, Boosts 2025 Revenue Guidance - AInvest
Pacira BioSciences (PCRX) Bolsters Growth with Strategic Moves - GuruFocus
Pacira BioSciences Inc (PCRX) Q2 2025 Earnings Call Highlights: Strong Growth in EXPAREL Sales ... - Yahoo Finance
Pacira BioSciences Inc (PCRX) Q2 2025 Earnings Call Highlights: Strong Growth in EXPAREL Sales ... By GuruFocus - Investing.com Canada
Pacira BioSciences' Q2 2025: Contradictions Surface on EXPAREL Market Access, Sales, and Margins - AInvest
Pacira BioSciences Q2 2025 Earnings Call Transcript: Key Takeaways - AInvest
Pacira BioSciences Inc (PCRX) Q2 2025 Earnings Call Highlights: - GuruFocus
Pacira BioSciences Q2 2025 Earnings Call Transcript - MarketBeat
Pacira BioSciences Reports Q2 2025 Financial Results - TipRanks
Decoding Pacira BioSciences Inc (PCRX): A Strategic SWOT Insight - GuruFocus
Pacira BioSciences: A Strategic Turnaround in the Opioid-Alternative Sector - AInvest
Pacira Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Pacira BioSciences' Q2 revenue misses estimates - MarketScreener
Pacira BioSciences reports Q2 2025 rev. $181.1mln, net loss $4.8mln. - AInvest
Pacira BioSciences Reports Second Quarter 2025 Financial Results - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Exit strategy if you’re trapped in Pacira BioSciences Inc.Risk Balanced Picks for Safer Trading - Newser
What To Expect From Pacira BioSciences Inc (PCRX) Q2 2025 Earnings - Yahoo Finance
What makes Pacira BioSciences Inc. stock price move sharplyCapitalize on market momentum for maximum profit - Jammu Links News
What are analysts’ price targets for Pacira BioSciences Inc. in the next 12 monthsRapid market gains - Jammu Links News
What is the dividend policy of Pacira BioSciences Inc. stockMarket-beating returns - Jammu Links News
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Investors to Inquire about Securities Investigation - ACCESS Newswire
What is the risk reward ratio of investing in Pacira BioSciences Inc. stockStay informed with expert market forecasts - Jammu Links News
What analysts say about Pacira BioSciences Inc. stockBuild wealth faster with expert stock selection - Jammu Links News
What are the latest earnings results for Pacira BioSciences Inc.Massive profits - Jammu Links News
How does Pacira BioSciences Inc. compare to its industry peersMarket-crushing profits - Jammu Links News
Pacira BioSciences (PCRX) Projected to Post Quarterly Earnings on Tuesday - Defense World
How volatile is Pacira BioSciences Inc. stock compared to the marketUnlock powerful portfolio management tools - Jammu Links News
How does Pacira BioSciences Inc. generate profit in a changing economyMarket-leading growth rates - Jammu Links News
Why is Pacira BioSciences Inc. stock attracting strong analyst attentionFree Stock Market Mentorship - Jammu Links News
0.43%
0.47%
자본화:
|
볼륨(24시간):